Early Phase 1 Obesity Trial, Recruiting NCT06392854 Sponsor: Mayo Clinic Condition: Obesity
Back to Obesity

Early Phase 1 Obesity Trial, Recruiting

NCT06392854
Recruiting Early Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Adults between 18 and 65 years old who can understand instructions, follow study procedures, and are willing to sign a consent form.
  • People with a body mass index (BMI) between 29.0 and 37.0, meaning they are in the overweight to obese range.
  • People whose excess weight is stored mostly around the belly area (upper body/visceral obesity), as measured by waist-to-hip ratio, body scans, or certain blood test results, based on specific cut-off values for men and women.
  • People whose excess weight is stored mostly in the lower body (such as hips and thighs), based on waist-to-hip ratio, body scans, or blood test results, with separate definitions applying to men and women.
  • Women who are not currently pregnant or breastfeeding, and who return a negative pregnancy test both at the screening stage and on the day of the inpatient visit.
  • Participants must be willing to eat all meals provided by the study unit for the 3 days leading up to the study, following a specially controlled diet.

Who may not be able to join:

  • People with a history of ischemic heart disease (reduced blood flow to the heart).
  • People with a history of atherosclerotic valvular disease (heart valve problems caused by fatty buildup in arteries).
  • People whose blood pressure remains above 160/95 even while taking blood pressure medication.
  • People who currently smoke.
  • People who have been diagnosed with diabetes.
  • People currently taking certain medications that can affect how the body processes fats, including niacin, thiazolidinediones, beta-blockers, corticosteroids (oral or injected), or anabolic steroids.
  • People with an allergy to lidocaine (a local anaesthetic).
  • People with an allergy to indocyanine green (a dye used in medical imaging).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Early Phase 1 studies are small, early exploratory studies that come before the main Phase 1 to 3 testing, so a standard phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Early Phase 1
Sponsor
Registry
ClinicalTrials.gov
Start date
1 May 2024
Est. completion
1 June 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

palmitate release

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov